Margaret Ancona is a distinguished healthcare executive with more than 25 years of experience in biotechnology, strategy, and organizational transformation. She most recently served as Executive Vice President of Strategy and Transformation at Myriad Genetics Inc., a leading molecular diagnostics company specializing in hereditary cancer testing and precision medicine. In this role, Ancona spearheaded the company's long-term strategic planning, overseeing initiatives that enhanced operational efficiency, expanded market access, and integrated advanced genomic technologies into clinical workflows. Her leadership was instrumental in navigating Myriad through a period of rapid industry evolution, including the shift toward companion diagnostics and value-based care models. Prior to joining Myriad in 2018, Ancona held senior leadership positions at prominent organizations such as Genentech and McKinsey & Company, where she advised on multi-billion-dollar mergers, digital health transformations, and global market expansions. At Genentech, she led cross-functional teams that accelerated product launches and improved supply chain resilience, contributing to significant revenue growth. Her achievements include authoring influential white papers on genomic data utilization and receiving the Healthcare Businesswomen's Association Rising Star Award for her innovative approaches to biotech strategy. Ancona's tenure at Myriad culminated in the successful execution of a comprehensive transformation roadmap that positioned the company for sustainable growth, including partnerships with major health systems and the adoption of AI-driven analytics for risk assessment. Now as a former EVP, she continues to influence the industry as a board advisor and speaker on healthcare innovation, drawing on her MBA from Harvard Business School and deep expertise in leveraging genetics for personalized medicine.